The next-generation multiple myeloma industry grows at 5.4% CAGR to US$37.07 billion by 2033, propelled by SWIFT-seq biopsies and NCCN preferences. Learn about 45% complete responses from Lynozyfic, and global shifts toward tailored, high-remission treatments for smoldering myeloma. https://finance.yahoo.com/news/next-generation-multiple-myeloma-therapies-112000005.html